Cel Sci CVM
NYSE CVM
$1.42 -0.04 (-2.74%)
At close: Aug 21, 2026 · 4:00 PM EDT

Cel Sci (CVM) Income towards Parent Company (2010 - 2026)

Cel Sci (CVM) posted Income towards Parent Company of -$13.0 million for Q1 2026, down 134.11% sequentially from -$5.5 million in Q4 2025, and down 97.11% YoY from -$447.6 million in Q1 2025.

Cel Sci (CVM) Income towards Parent Company (2010 - 2026) Analysis & Trends

Cel Sci has reported Income towards Parent Company for 17 years, with the latest figure at -$13.0 million in Q1 2026.

  • Quarterly Income towards Parent Company fell 97.11% year-over-year to -$13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.6 million (down 52.22% YoY) and the FY2025 annual result came in at -$90.7 million, down 2.09% from the prior year.
  • Income towards Parent Company retreated to -$13.0 million in Q1 2026 per CVM's latest filing, from -$5.5 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$5.5 million in Q4 2025 and troughed at -$15.2 million in Q2 2025.
  • A 5-year average of -$8.5 million and a median of -$7.9 million in 2025 frame the typical range for Income towards Parent Company.
  • The widest YoY moves for Income towards Parent Company: up 22.08% in 2025, down 102.5% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$8.0 million in 2022, then increased by 16.39% to -$6.7 million in 2023, then fell by 5.84% to -$7.1 million in 2024, then climbed by 22.08% to -$5.5 million in 2025, then sank by 134.11% to -$13.0 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$13.0 million, -$5.5 million, and -$7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Cel Sci 2.12 Mn -4.42 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -12.95 Mn
Dec 31, 2025 -5.53 Mn
Sep 30, 2025 -7.92 Mn
Jun 30, 2025 -15.22 Mn
Mar 31, 2025 -6.57 Mn
Dec 31, 2024 -7.10 Mn
Sep 30, 2024 -6.16 Mn
Jun 30, 2024 -7.52 Mn
Mar 31, 2024 -7.24 Mn
Dec 31, 2023 -6.71 Mn
Sep 30, 2023 -7.63 Mn
Jun 30, 2023 -8.37 Mn
Mar 31, 2023 -8.34 Mn
Dec 31, 2022 -8.03 Mn
Sep 30, 2022 -9.10 Mn
Jun 30, 2022 -9.93 Mn
Mar 31, 2022 -9.82 Mn
Dec 31, 2021 -9.13 Mn
Sep 30, 2021 -8.60 Mn
Jun 30, 2021 -10.48 Mn